Methods for the analysis of continuous biomarker assay data with increased sensitivity

Epidemiology

Volumn 15, Issue 6, 2004, Pages 724-732

  Lau, Bryan ^a   Gange, Stephen J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TECHNOLOGY;

ALGORITHMS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 15744393685     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000142154.86749.e4     Document Type: Article

References (28)

1. Schulte PA, Perera FP. Molecular Epidemiology Principles and Practices. San Diego: Academic Press, Inc.; 1993.
2. Muñoz A, Gange SJ. Methodological issues for biomarkers and intermediate outcomes in cohort studies. Am J Epidemiol. 1999;20:29-42.
3. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
4. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321:1621-1625.
5. Coombs RW, Collier AC, Allain J-P, et al. Plasma viremia in human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1626-1632.
6. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
7. Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
8. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
9. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
10. Vandamme AM, Schmit JC, Van Dooren S, et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:127-139.
11. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology utilization for HIV-1 blood evaluation and standardization in pediatrics. J Clin Microbiol. 1998;36:1471-1479.
12. Kirstein LM, Mellors JW, Rinaldo CR, et al. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol. 1999;37:2428-2433.
13. Lang JR, Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry-1. Experimental considerations. J Pharm Biomed Anal. 1991;9:357-361.
14. Lang JR, Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry-2. Statistical analyses. J Pharm Biomed Anal. 1991;9:435-442.
15. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med. 2000;19:3171-3191.
16. Kleeberger CA, Lyles RH, Margolick JB, et al. Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol. 1999;6:14-19.
17. Moulton LH, Curriero FC, Barroso PF. Mixture models for quantitative HIV RNA data. Stat Methods Med Res. 2002;11:317-325.
18. Lynn HS. Maximum likelihood inference for left-censored HIV RNA data. Stat Med. 2001;20:33-45.
19. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352:1510-1514.
20. Anastos K, Gange SJ, Lau B, et al. The association of race and gender with HIV-1 RNA levels and immunologic progression. JAIDS. 2000;24:218-226.
21. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Inter-agency HIV Study. Epidemiology. 1998;9:117-125.
22. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
23. Marschner IC, Betensky RA, DeGruttola V, et al. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:220-227.
24. Jacqmin-Gadda H, Thiebaut R, Chene G, et al. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics. 2000;1:355-368.
25. Little RJ, Rubin DB. Statistical Analysis with Missing Data. New York: Wiley; 1987.
26. Muñoz A, Carey V, Taylor JMG, et al. Estimation of time since exposure for a prevalent cohort. Statistics in Medicine. 1992;11:939-952.
27. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
28. Lau B. Methods for Adapting Biomarker Assays with Increased Sensitivity in Prospective Cohort Studies: Application to HIV RNA in the Women's Interagency HIV Study. [dissertation]. Baltimore, MD: Johns Hopkins School of Public Health; 2000.